{"type":"trials","record":{"id":41530,"source_id":"clinicaltrials-gov","external_id":"NCT06722157","title":"A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy","brief_summary":"This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan. BI 771716 is being developed to treat people with geographic atrophy. Pegcetacoplan is a medicine already used to treat people with geographic atrophy. In this study, participants receive either BI 771716 or pegcetacoplan as injections in the eye. Participants are in the study for a little longer than a year and visit the study site every 4 weeks. At the visits, the study doctor checks the eyes of the participants. The results are compared between the groups of participants to see whether the treatment works. The study doctor also regularly checks participants' health and takes note of any unwanted effects.","overall_status":"Active Not Recruiting","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Boehringer Ingelheim","enrollment":202,"countries":["United States"],"start_date":"2025-01-06","completion_date":"2026-10-28","last_update_date":"2026-05-14","source_url":"https://clinicaltrials.gov/study/NCT06722157","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"VERDANT","age_range":"50 Years","comparator":"Arm C: Pegcetacoplan","organization":"Boehringer Ingelheim","interventions":["BI 771716","Pegcetacoplan","Sham comparator to BI 771716"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Slope of change from baseline in square root transformed geographic atrophy (GA) area as measured by fundus autofluores…","Change from baseline in square root transformed GA area as measured by FAF in the study eye expressed in mm — At Baseli…","Change from baseline in best corrected visual acuity (BCVA) as measured by standardized early trial diabetic retinopath…","Occurrence of BCVA letter loss of ≥15 letters as measured by standardized ETDRS chart in the study eye for at least 2 c…","Occurrence of exudative neovascular age-related macular degeneration (eAMD) in the study eye from first drug administra…","Occurrence of drug-related adverse events (AE) from first drug administration until Week 56 — Up to Week 56"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Macular Degeneration, Age-related","Geographic Atrophy","BI 771716","Pegcetacoplan","Sham comparator to BI 771716"],"relevance_confidence":80,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06722157","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-01-06 to 2026-10-28","comparator":"Arm C: Pegcetacoplan","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.828Z","intervention":["BI 771716","Pegcetacoplan","Sham comparator to BI 771716"],"participants":202,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Slope of change from baseline in square root transformed geographic atrophy (GA) area as measured by fundus autofluores…","Change from baseline in square root transformed GA area as measured by FAF in the study eye expressed in mm — At Baseli…","Change from baseline in best corrected visual acuity (BCVA) as measured by standardized early trial diabetic retinopath…","Occurrence of BCVA letter loss of ≥15 letters as measured by standardized ETDRS chart in the study eye for at least 2 c…","Occurrence of exudative neovascular age-related macular degeneration (eAMD) in the study eye from first drug administra…","Occurrence of drug-related adverse events (AE) from first drug administration until Week 56 — Up to Week 56"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","title context","study type"],"relevance_score":80,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41530","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}